Bolt Biotherapeutics, Inc. (BOLT)
NASDAQ: BOLT · IEX Real-Time Price · USD
0.930
+0.030 (3.32%)
At close: Nov 27, 2023, 4:00 PM
0.910
-0.020 (-2.14%)
After-hours: Nov 27, 2023, 5:49 PM EST
Bolt Biotherapeutics Revenue
Bolt Biotherapeutics had revenue of $7.20M in the twelve months ending September 30, 2023, with 49.15% growth year-over-year. Revenue in the quarter ending September 30, 2023 was $2.53M with 19.70% year-over-year growth. In the year 2022, Bolt Biotherapeutics had annual revenue of $5.73M with 354.68% growth.
Revenue (ttm)
$7.20M
Revenue Growth
+49.15%
P/S Ratio
4.90
Revenue / Employee
$76,574
Employees
94
Market Cap
35.30M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 5.73M | 4.47M | 354.68% |
Dec 31, 2021 | 1.26M | 1.03M | 445.45% |
Dec 31, 2020 | 231.00K | 16.00K | 7.44% |
Dec 31, 2019 | 215.00K | - | - |
Dec 31, 2018 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Retractable Technologies | 41.99M |
Co-Diagnostics | 4.66M |
IceCure Medical | 2.91M |
BeyondSpring | 1.35M |
OncoCyte | -2.36M |
BOLT News
- 18 days ago - Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update - GlobeNewsWire
- 5 weeks ago - Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress - GlobeNewsWire
- 5 weeks ago - Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers - GlobeNewsWire
- 6 weeks ago - Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023 - GlobeNewsWire
- 2 months ago - Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers - GlobeNewsWire
- 2 months ago - Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042 - GlobeNewsWire
- 2 months ago - Bolt Biotherapeutics to Participate in September Investor Conferences - GlobeNewsWire
- 4 months ago - Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update - GlobeNewsWire